2-羟基-6-三氟甲基苯甲酸甲酯 | 1024605-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-6-三氟甲基苯甲酸甲酯
• 英文名称: 2-hydroxy-6-trifluoromethylbenzoic acid methyl ester
• 英文别名: Methyl 2-hydroxy-6-(trifluoromethyl)benzoate；methyl 2-hydroxy-6-(trifluoromethyl)benzoate
• CAS: 1024605-95-5
• 化学式: C₉H₇F₃O₃
• 分子量: 220.148
• InChiKey: GZORLGIQLIGJHI-UHFFFAOYSA-N

物化性质

• 沸点：
  252.3±40.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-羟基-6-三氟甲基苯甲酸甲酯 、 甲基溴化镁 在 三乙胺 作用下， 以 乙醚 、 甲苯 为溶剂， 以55%的产率得到1-(2-羟基-6-三氟甲基苯基)乙酮
  参考文献：
  名称：

  Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

  摘要：

  Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.043
• 作为产物：
  描述：

  甲醇 、 2-trifluoromethyl-6-hydroxybenzoic acid 在 三甲基硅烷化重氮甲烷 作用下， 以 正己烷 、 乙酸乙酯 为溶剂， 以93%的产率得到2-羟基-6-三氟甲基苯甲酸甲酯
  参考文献：
  名称：

  Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

  摘要：

  Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.043

文献信息

• Enzyme-catalysed synthesis and reactions of benzene oxide/oxepine derivatives of methyl benzoates
  作者：Derek R. Boyd、Narain D. Sharma、John S. Harrison、John. F. Malone、W. Colin McRoberts、John T. G. Hamilton、David B. Harper

  DOI：10.1039/b718375e

  日期：——

  substituted benzene oxide metabolite of methyl 2-(trifluoromethyl)benzoate, which slowly converted into the racemic form. The arene oxide was found to undergo a cycloaddition reaction with 4-phenyl-1,2,4-triazoline-3,5-dione to yield a crystalline cycloadduct whose structure and racemic nature was established by X-ray crystallography. The metabolite was also found to undergo some novel benzene oxide reactions

  一系列十二种苯甲酸酯被木材腐烂真菌的桑黄属物种代谢，产生相应的苯甲醇衍生物和八种水杨酸酯。从苯甲酸甲酯中分离出稳定的氧杂环丁烷代谢物，与在烷基苯甲酸烷基酯的酶催化邻羟基化反应形成水杨酸酯的过程中碳甲氧基团的迁移和保留（NIH转变）的证据相一致。最初的芳烃环氧化步骤。通过分离2-（三氟甲基）苯甲酸甲酯的显着稳定的，光学活性的，取代的苯氧化物代谢物，证实了该机理，该产物缓慢转化为外消旋形式。发现氧化芳烃与4-苯基-1,2,4-三唑啉-3发生环加成反应，5-二酮产生结晶的环加合物，其结构和外消旋性质是通过X射线晶体学确定的。还发现该代谢物经历了一些新颖的苯氧化物反应，包括环氧化以生成抗二环氧化合物，碱催化的水解以形成反式二氢二醇，以及酸催化的芳构化通过碳氢甲氧基的NIH转移产生水杨酸酯衍生物。 。
• POLYURETHANE, POLYURETHANE PRODUCTION METHOD, CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE
  申请人：Shin-Etsu Chemical Co., Ltd.

  公开号：EP4001336A1

  公开（公告）日：2022-05-25

  A polyurethane contains a weakly acidic functional group having a pKa of 5 to 11. Thus, the present invention provides: a conductive paste composition for forming a stretchable conductive wire which varies slightly in electric conductivity at the time of elongation and shrinkage; and a polyurethane for providing the composition.

  聚氨酯含有 pKa 值为 5 至 11 的弱酸性官能团。因此，本发明提供了：一种用于形成可拉伸导电线的导电浆料组合物，该导电浆料组合物在拉伸和收缩时导电率略有不同；以及一种用于提供该组合物的聚氨酯。
• Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4′-piperidine] analogs
  作者：Yoshikazu Uto、Yuko Ueno、Yohei Kiyotsuka、Yuriko Miyazawa、Hitoshi Kurata、Tsuneaki Ogata、Makiko Yamada、Tsuneo Deguchi、Masahiro Konishi、Toshiyuki Takagi、Satoko Wakimoto、Jun Ohsumi

  DOI：10.1016/j.ejmech.2010.07.044

  日期：2010.11

  In continuation of our investigation on novel stearoyl-CoA desaturase (SCD) 1 inhibitors, we have already reported on the structural modification of the benzoylpiperidines that led to a series of novel and highly potent spiropiperidine-based SCD1 inhibitors. In this report, we would like to extend the scope of our previous investigation and disclose details of the synthesis, SAR, ADME, PK, and pharmacological evaluation of the spiropiperidines with high potency for SCD1 inhibition. Our current efforts have culminated in the identification of 5-fluoro-1'-6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] (10e), which demonstrated a very strong potency for liver SCD1 inhibition (ID(50) = 0.6 mg/kg). This highly efficacious inhibition is presumed to be the result of a combination of strong enzymatic inhibitory activity (IC(50) (mouse)= 2 nM) and good oral bioavailability (F >95%). Pharmacological evaluation of 10e has demonstrated potent, dose-dependent reduction of the plasma desaturation index in C57BL/6J mice on a high carbohydrate diet after a 7-day oral administration (q.d.). In addition, it did not cause any noticeable skin abnormalities up to the highest dose (10 mg/kg). (C) 2010 Elsevier Masson SAS. All rights reserved.